Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 9Uterine Cervical Neoplasms 7Colonic Neoplasms 6Breast Neoplasms 5Uterine Cervical Dysplasia 4Urinary Bladder Neoplasms 4Papillomavirus Infections 3Neuroblastoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Brain Neoplasms 3Anus Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Intraepithelial Lesions 2Rectal Neoplasms 2Precancerous Conditions 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2HIV Infections 2Gallbladder Neoplasms 2

Interventions

tremelimumab 1pembrolizumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Watchful Waiting 1Radiotherapy 1Palliative Care 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Muscle-invasive Bladder Cancer × Watchful Waiting × Clear all
NCT06686381 2025-02-05

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

American University of Beirut Medical Center

Phase 2 Not yet recruiting
80 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡